A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.
about
A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaAnalysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.In vitro indeterminate teleost myogenesis appears to be dependent on Pax3Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodelingForetinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.Targeting the HGF/Met signalling pathway in cancer.Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.A highly invasive human glioblastoma pre-clinical model for testing therapeutics.Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infectionMultispectral imaging: a review of its technical aspects and applications in anatomic pathology.Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).
P2860
Q28487973-38FB7968-9377-475A-8A73-2C5E5FB2C3CCQ33649756-95419D67-1E6B-4F9F-9F96-B8C9E033A121Q33750177-C462EABE-C7F2-4235-A803-ED8A4A7F1A31Q34138165-08FA2C37-74CC-4D87-8117-9519E39B7750Q35036800-2AA8D982-81DC-424A-A3EC-E19999B85646Q35203637-4B1EA246-436B-4D2A-A56D-380AC39D10C8Q36095630-EC4F1E5F-A94F-4B68-8B44-7BD1449A5095Q36142604-EC1185B9-A25C-46B2-8A68-727330E6EAE5Q36290408-64A0BC1B-5858-4F01-ABEC-BE23D3D674C0Q37022410-03BCE7C0-0CE3-4DBC-9505-8E62EEECB9FAQ37103825-B72AAE67-D228-4173-90E7-88A0B0AD09FAQ37293205-9A688818-4233-4B83-AF77-0A35DCA49600Q37346559-551FB5B0-EC8A-43D2-9DEA-8724D8F2FEC3Q37688459-5A3E55EC-C9B5-40CA-A153-B58F1CCC92B4Q37735662-CAB037F5-7815-4D23-B405-9E137B48F24AQ38152999-AAA6492E-6881-486B-A4BF-FE29C6AA56EBQ39368513-3A5221CB-FE51-48E0-AD21-D1229AC3C39EQ42438922-3606F205-65F9-4190-8D67-8113B2777B6BQ42695141-520C95CE-C2D0-4016-A634-EAA8FF219824Q49651740-6F1DFC36-1763-45BA-86CB-8A04D6310152Q53058993-6BE4FBCF-C818-4765-A2E6-BD6300FDE07EQ53878549-5527CAC5-CE69-4A88-B0D8-62ACC5467C02
P2860
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A novel multipurpose monoclona ...... linical and clinical settings.
@ast
A novel multipurpose monoclona ...... linical and clinical settings.
@en
A novel multipurpose monoclona ...... linical and clinical settings.
@nl
type
label
A novel multipurpose monoclona ...... linical and clinical settings.
@ast
A novel multipurpose monoclona ...... linical and clinical settings.
@en
A novel multipurpose monoclona ...... linical and clinical settings.
@nl
prefLabel
A novel multipurpose monoclona ...... linical and clinical settings.
@ast
A novel multipurpose monoclona ...... linical and clinical settings.
@en
A novel multipurpose monoclona ...... linical and clinical settings.
@nl
P2093
P2860
P1476
A novel multipurpose monoclona ...... linical and clinical settings.
@en
P2093
Aviva Ventura
Beatrice S Knudsen
Bree Berghuis
Eric Hudson
Ermanno Gherardi
Ernst Lengyel
George Vande Woude
P2860
P356
10.1097/PAI.0B013E3181816AE2
P577
2009-01-01T00:00:00Z